Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment January 10, 2025
Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development December 16, 2024
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise November 11, 2024
